A Study Evaluating Atezolizumab And Bevacizumab, With Or Without Tiragolumab, In Participants With Untreated Locally Advanced Or Metastatic Hepatocellular Carcinoma (Imbrave152) (Skyscraper-14)
Posted Date: Apr 26, 2024
- Investigator: Davendra Sohal
- Specialties:
- Type of Study: Drug
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC).
Criteria:
Null
Keywords:
Liver Cancer
For More Information:
Haley Appelmann
NULL
cancer@uchealth.com